NewAmsterdam Pharma
NAMS
14 hedge funds and large institutions have $362M invested in NewAmsterdam Pharma in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
41.09% more ownership
Funds ownership: 0% → 41.09% (+41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$92.8M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$82.5M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$39.8M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$37.3M |
| 5 |
DM
Deerfield Management
New York
|
+$24.7M |
Top Sellers
NAMS Hedge Fund Activity: Q4 2022 in Review
14 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q4 2022, worth a combined $362M.
Buyers outnumbered sellers: 14 funds opened new NAMS positions and 0 closed out — a net gain of 14 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $92.8M.
- 14 institutional investors held NewAmsterdam Pharma (NAMS) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $362M of NewAmsterdam Pharma stock for Q4 2022.
- 14 funds opened new NewAmsterdam Pharma positions in Q4 2022 and 0 closed out, a net change of +14 holders.
- The largest NewAmsterdam Pharma buyer in Q4 2022 was Frazier Life Sciences Management, an estimated $92.8M added.
Based on aggregated 13F filings for Q4 2022.